The County of San Diego’s thresholds for exempting certain projects from vehicle miles traveled (VMT) analysis were not supported by ...

Perspective Therapeutics, Inc. presented updated interim results from its ongoing Phase 1/2a clinical trial of [212Pb]VMT-α-NET at the 2025 ASCO Annual Meeting, showing a favorable safety profile ...

This Phase 1/2a clinical trial is a multi-center open-label dose escalation and dose expansion study (clinicaltrials.gov identifier NCT05636618) of [212 Pb]VMT-α-NET in patients with unresectable ...

This Phase 1/2a clinical trial is a multi-center open-label dose escalation and dose expansion study (clinicaltrials.gov identifier NCT05636618) of [212 Pb]VMT-α-NET in patients with unresectable or ...

Throughout the United States, less housing has been built in walkable communities since 2010 despite hopes of increased ...

The daily struggle for citizens in Africa’s most populous nation offers a market opportunity to drive inclusive prosperity.

The Seattle-based company came to ASCO25 with new data on its neuroendocrine tumor–treating lead therapy, with big vibes and ...

In 2007, architect Carl Elefante expressed an idea that has since become a common provocation in the world of architecture: ...

Perspective Therapeutics, Inc. (NYSE:CATX) has announced encouraging interim results from its ongoing Phase 1/2a clinical ...